Neuspera Medical®, has recently launched a groundbreaking peripheral nerve stimulation device called the Neuspera ultra-miniaturized system.
This innovative device has received approval from the United States Food and Drug Administration (FDA).
The Neuspera system utilizes a micro-implant to deliver neurostimulation therapy, which is facilitated by a wireless platform consisting of a wearable transmitter and an iPad-based clinician programmer.
Compared to existing commercial technology, the Neuspera system offers a wireless, less invasive, and highly adaptable approach to peripheral nerve stimulation (PNS). It stands out as the first PNS device to provide an ultra-miniaturized alternative, enhancing the patient experience and offering greater procedural flexibility.
Remarkably, the Neuspera device is 75 times smaller than the smallest currently available implantable pulse generator, enabling clinicians to target deeper anatomical structures that were previously challenging to reach.
Peripheral nerve stimulation (PNS) has gained significant recognition as an effective treatment option for chronic pain disorders. With the increasing prevalence of chronic pain, advancements in implantable device technology, and the growing demand for alternative pain management approaches, the PNS market is projected to experience substantial growth.
